A carregar...
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
Na minha lista:
Publicado no: | Pharmacoeconomics |
---|---|
Main Authors: | , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Springer International Publishing
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://ncbi.nlm.nih.gov/pubmed/26792791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0380-x |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|